Inhibition of the Stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease.
Stem cell factor (SCF) and its receptor c-kit have been implicated in inflammation, tissue remodeling, and fibrosis. Ingenuity® Integrated Pathway Analysis (IPA) of gene expression array datasets showed an upregulation of SCF transcripts in IPF lung biopsies compared to tissue from non-fibrotic lungs that are further increased in rapid progressive disease. SCF248, a cleavable isoform of SCF, was abundantly and preferentially expressed in human lung fibroblasts and fibrotic mouse lungs relative to the SCF220 isoform. In fibroblast-mast cell co-culture studies, blockade of SCF248 using a novel isoform specific anti-SCF248 monoclonal antibody (anti-SCF248), attenuated the expression of COL1A1, COL3A1 and FN1 transcripts in co-cultured IPF but not normal lung fibroblasts. Administration of anti-SCF248 on days 8 and 12 after bleomycin instillation in mice significantly reduced fibrotic lung remodeling and col1al, fn1, acta2, tgfb and ccl2 transcript expression. In addition, bleomycin increased numbers of c-kit+ mast cells, eosinophils and ILC2 in lungs of mice, whereas they were not significantly increased in anti-SCF248 treated animals. Finally, mesenchymal cell specific deletion of SCF significantly attenuated bleomycin-mediated lung fibrosis and associated fibrotic gene expression. Collectively, these data demonstrate that SCF is upregulated in diseased IPF lungs and blocking SCF248 isoform significantly ameliorates fibrotic lung remodeling in vivo, suggesting that it may be a therapeutic target for fibrotic lung diseases.